Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganovo + ritonavir and integrated Chinese-Western medicine for COVID-19
ChiCTR2000030000Phase 4Recruiting
- Sponsor
- Nanchang Ninth Hospital
- Start
- Feb 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of danoprevir and ritonavir in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (5 arms), sponsored by Nanchang Ninth Hospital. Primary endpoint: Rate of composite adverse outcomes. Started Feb 2020; status: recruiting.
02
Drugs
danoprevirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2000030000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030000.